We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+4.55%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$240M
AUM Growth
-$595K
Cap. Flow
-$624K
Cap. Flow %
-0.26%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$320K

Top Sells

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$944K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$80.3M 33.41%
19,963,157
– –
AURA icon
2
Aura Biosciences
AURA
$725M
$55.1M 22.93%
3,039,892
– –
PCVX icon
3
Vaxcyte
PCVX
$7.81B
$45.3M 18.86%
1,887,478
– –
MRUS
4
DELISTED
Merus
MRUS
$32M 13.34%
1,600,000
– –
PHAT icon
5
Phathom Pharmaceuticals
PHAT
$708M
$27.5M 11.46%
2,484,274
+33,595
+1% +$320K
OBSV
6
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-1,570,000
Closed -$944K

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q3 2022 Portfolio in Review

As of Q3 2022, Medicxi Ventures Management held 6 positions worth $240M, down 0.25% from $241M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management's Q3 2022 filing shows 1 increased and 1 closed positions. The largest sale was ObsEva SA Ordinary Shares, an estimated $944K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management added most to Phathom Pharmaceuticals in Q3 2022, an estimated $320K increase.
  • Medicxi Ventures Management fully exited ObsEva SA Ordinary Shares in Q3 2022, selling an estimated $944K.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $240M portfolio in Q3 2022.
  • Medicxi Ventures Management opened 0 new positions and closed 1 in Q3 2022.
  • Medicxi Ventures Management's portfolio value fell 0.25% quarter-over-quarter to $240M.

Based on Medicxi Ventures Management's 13F filing for Q3 2022, filed 25 Oct 2022.